Latrepirdine
- Generic Name
- Latrepirdine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3
- CAS Number
- 3613-73-8
- Unique Ingredient Identifier
- OD9237K1Z6
- Background
Latrepirdine has been investigated for the treatment of Alzheimer's Disease and Huntington's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00827034
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New Haven, Connecticut, United States
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00825084
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Glendale, California, United States
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2009-12-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00824590
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, St. Paul, Minnesota, United States
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00704782
- Locations
- ๐บ๐ธ
Xenoscience, Inc., Phoenix, Arizona, United States
๐บ๐ธBanner Alzheimer's Institute, Phoenix, Arizona, United States
๐บ๐ธSun Health Research Institute, Sun City, Arizona, United States
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 598
- Registration Number
- NCT00675623
A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT00497159
- Locations
- ๐บ๐ธ
Huntington Study Group, Rochester, New York, United States
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2008-01-04
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00387270
- Locations
- ๐บ๐ธ
Huntington Study Group, Rochester, New York, United States
Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT00377715
- Locations
- ๐ท๐บ
Mental Health Research Center of Russian Academy of Medical Sciences, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.